It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response in patients, however, there has recently been an increased demand for type O female blood-derived iPSCs.
Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...
Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology firm, has announced a strategic collaboration with Greenstone Biosciences Inc. to utilize Artificial Intelligence (AI) in ...
Leadership Perspective “Creative Medical is at the forefront of regenerative medicine, and our extended partnership with Greenstone Biosciences marks a significant milestone in our mission to develop ...
Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.